Table 2. Variations of indices after treatment for 12 weeks.

Term	Lira group (n=52)	Met group (n=75)	t	P
Weight (kg)	76.09 ± 9.85	77.22 ± 10.151	−2.764	0.02
BMI (kg/m2)	25.87 ± 1.49	26.91 ± 1.731	−2.28	0.02
WHR	0.95 ± 0.05	0.96 ± 0.042	−2.59	0.009
TC (mmol/l)	4.88 ± 1.51	4.82 ± 0.92	−0.09	0.954
TG (mmol/l)	1.84 ± 0.60	1.78 ± 0.51	0.95	0.325
LDL (mmol/l)	2.46 ± 0.53	2.45 ± 0.55	−0.029	0.687
HDL (mmol/l)	1.05 ± 0.24	1.03 ± 0.20	1.034	0.081
ALT (U/l)	39.82 ± 14.05	51.48 ± 18.892	−3.36	0.000
AST (U/l)	25.61 ± 7.87	31.54 ± 10.751	2.62	0.012
AST/ALT	0.81 ± 0.17	0.69 ± 0.152	4.34	0.00
FPG (mmol/l)	7.11 ± 0.68	7.32 ± 0.76	−1.52	0.131
2hPG (mmol/l)	10.31 ± 3.17	12.05 ± 4.03	−2.43	0.024*
HbA1C (%)	7.23 ± 0.68	7.20 ± 0.37	0.32	0.749
HOMA-IR	2.47 ± 0.44	2.48 ± 0.51	−0.10	0.923
APN (mg/l)	10.44 ± 3.29	8.43 ± 2.312	3.45	0.000
CRP (mg/l)	2.18 ± 0.34	2.69 ± 0.531	−3.21	0.023
CK18 (IU/l)	228.36 ± 41.09	217.05 ± 37.84	1.60	0.112
Side effect (number)	9	4	-	-

Compared with the Lira group. Abbreviation: CK18, cytokeratin 18.

¹P<0.05.

²P<0.01.